AB205. SOH26AB_0192. Pancreatectomy for metastatic renal cell carcinoma: a case series of 11 patients from a tertiary centre
General Surgery Posters I

AB205. SOH26AB_0192. Pancreatectomy for metastatic renal cell carcinoma: a case series of 11 patients from a tertiary centre

Nina Carlos-De Clercq1, Stephen O’Brien1,2, Brian Hayes3, Criostóir Ó Súilleabháin1,2, Adrian O’Sullivan1,2

1Department of Hepatobiliary Surgery, Cork University Hospital, Cork, Ireland; 2Department of Hepatobiliary Surgery, Mercy University Hospital, Cork, Ireland; 3Department of Pathology, Cork University Hospital, Cork, Ireland

Background: Pancreatic metastases account for only 2–5% of malignant pancreatic lesions, with renal cell carcinoma (RCC) being the most common primary source. Current guidelines support metastasectomy for oligometastatic disease following multidisciplinary team (MDT) review. This study presents an Irish case series evaluating outcomes following pancreatectomy for metastatic RCC.

Methods: A consecutive series of 11 patients underwent pancreatic resection for RCC metastases between 2011 and 2025. Demographics, comorbidities, operative details, pathology, and clinical outcomes were recorded. Survival outcomes were assessed using Kaplan-Meier analysis.

Results: Eleven patients underwent surgery for isolated RCC pancreatic metastases. Median age at RCC diagnosis was 62 (range, 37–81) years, with a median interval to metastasis of 8 (range, 1–25) years. One patient underwent synchronous nephrectomy and pancreatic metastasectomy. All patients achieved R0 (no residual tumour) resection [n=4 pylorus-preserving pancreaticoduodenectomy (PPPD); n=3 distal/subtotal pancreatectomy; n=3 total pancreatectomy]. Major postoperative complications (Clavien-Dindo ≥ IIIa) occurred in 3 patients (27%). Median length of stay was 14 days. Four patients developed recurrence at a non-pancreatic site (median, 7 months). One patient who initially underwent PPPD developed a pancreatic tail recurrence and proceeded to completion pancreatectomy. Median overall survival from RCC diagnosis was 157 months, and median survival from diagnosis of pancreatic metastasis was 83 months.

Conclusions: Pancreatic resection for RCC metastasis is feasible in well-selected patients and yields favourable long-term oncological outcomes, aligning with international experience. Careful patient selection and discussion at both urology and hepatobiliary MDT meetings remain essential.

Keywords: Metastasectomy; pancreatectomy; pancreatic metastases; renal cell carcinoma (RCC); survival outcomes

Acknowledgments

None.

Footnote

Funding: None.

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-26-ab205
Cite this abstract as: Clercq NCD, O’Brien S, Hayes B, Súilleabháin CÓ, O’Sullivan A. AB205. SOH26AB_0192. Pancreatectomy for metastatic renal cell carcinoma: a case series of 11 patients from a tertiary centre. Mesentery Peritoneum 2026;10:AB205.

Article Options

Download Citation

Share